Navigation Links
Douglas Harrington, MD Speaks at American Academy of Physicians Assistants 2013 Conference in Washington, DC
Date:5/29/2013

IRVINE, Calif., May 29, 2013 /PRNewswire/ -- Aviir, Inc. attended the AAPA's Impact 2013 conference in Washington DC, as guests of GUARDaHEART, a non-profit foundation focused on Heart Disease awareness, at the Walter E. Washington Convention Center on May 28-29. Aviir's Chief Executive Officer Douglas Harrington , MD, presented on May 28, in the Product Theatre.

(Logo:  http://photos.prnewswire.com/prnh/20130319/LA79677LOGO)

"The presentation, 'Preventing Heart Disease: Identifying the Vulnerable Patient Before it is Too Late' discussed the clinical dilemma of at-risk patients being missed by current standard risk assessments, such as lipid panels and the Framingham ten year risk projection," said Dr. Harrington. "Fifty percent of heart attack patients have normal cholesterol levels, making early detection imperative to reducing risk before a cardiac event occurs and in halting disease progression early enough for the patient to improve their health."

During his presentation, Dr. Harrington also spoke about Aviir's MIRISK™ and MIRISK VP™ cardiac risk assessments. The MIRISK VP provides a net reclassification index improvement of 43 percent over Framingham, the current gold standard 10-year risk assessment, and was demonstrated in the MESA population. The test has applications across many medical specialties due to the prevalence of heart disease (750,000 new cases a year in the U.S. alone.).

Aviir has partnered with GUARDaHEART to promote Heart Disease awareness and prevention. Together, they have organized education events and fundraisers, and helped to make patient lifestyle modification a welcoming experience. GUARDaHEART's recommendations, activities, and events provide meaningful support and motivation to anyone interested in improving their heart health.

About Aviir
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

About GUARDaHEART 
GUARDaHEART is a non-profit foundation dedicated to raising awareness of Heart Disease prevention by spreading the word to guard your heart and save your life. Cardiovascular disease is the leading cause of death in the United States. The good news is if individuals know their risk and take the necessary steps, most cardiovascular disease can be prevented and reversed if detected early. Although heart disease is typically diagnosed in adulthood, its roots are often found in childhood. Compelling research has shown that plaque buildup in the arterial walls begins very early in life and progresses throughout life. Intervention strategies and healthy lifestyle modification to reduce heart disease risk should begin early when reversal of the process is easier, not later in life when the disease is more developed. GUARDaHEART Foundation also provides assistance for individuals who are unable to pay for cardiac risk assessments. Please visit www.guardaheart.org for more information.

Company Contacts:
For media inquiries, please contact:
Tamara York 
Tamara York Public Relations, LLC 
212.967.8300

For Investor Relations, please contact:
Matt Clawson 
Life Capital Partners 
949.370.8500


'/>"/>
SOURCE Aviir, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
2. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
3. Natalie Douglas, CEO von Idis, tritt Vorstand von Global Genes
4. RARE Project bei
5. Natalie Douglas, CEO of Idis, Joins Global Genes
6. RARE Project Board of Directors
7. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
8. World Renowned Scientist, Dr. Rongxiang Xu Speaks Out About Nobel Assembly Statement Claiming They Have Not Heard Of Him
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
11. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
(Date:5/23/2017)... ... 2017 , ... The National Council on Strength and Fitness ... organization’s Certified Strength Coach credential has earned accreditation from the National Commission for ... competency of qualified candidates for jobs in the Strength and Conditioning profession. The ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a ... in building collagen and elastin in their face, neck, and body through a ...
(Date:5/23/2017)... ... 23, 2017 , ... Drs. Allen Huang and Jeffrey Wang, ... Las Vegas, NV, and the importance of treating it immediately. They are now ... for peri-implantitis, with or without a referral. As experienced periodontists and implant specialists, ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... video chat as a standard feature on its secure clinical communication platform. The ... voice to video depending on the type and urgency of a situation. ...
Breaking Medicine News(10 mins):